LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Cutting Nuvalent, Inc. (NUVL) FY 26 Rev. Estimate To 0.7 M From 4.3 M 11/19/2025 11:45:05 PM
  • Wedbush Is Cutting Nuvalent, Inc. (NUVL) Q4 26 Rev. Estimate To 0.7 M From 3.2 M 11/19/2025 11:44:57 PM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $125 Price Target 11/19/2025 11:44:23 PM
  • Nuvalent Announces Pricing Of Public Offering Of 4.95 Mln Common Stock At $101/Shr 11/19/2025 12:00:02 AM
  • Wedbush Is Lowering Nuvalent, Inc. (NUVL) FY 25 Estimate To -5.72 From -4.24 11/17/2025 8:57:51 PM
  • Wedbush Is Cutting Nuvalent, Inc. (NUVL) Q4 25 Estimate To -1.45 From -1.14 11/17/2025 8:57:41 PM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $125 Up From $120 Price Target 11/17/2025 8:53:48 PM
  • Nuvalent Reports Positive ALKOVE-1 Data For Neladalkib In ALK+ NSCLC Patients 11/17/2025 6:45:07 AM
  • Nuvalent Presents Preliminary Data For Neladalkib In Advanced ALK-positive Solid Tumors Beyond NSCLC 10/18/2025 6:45:31 AM
  • Nuvalent Presents Data From ARROS-1 Trial Of Zidesamtinib For TKI Pre-treated Patients With Advanced ROS1-positive NSCLC 9/7/2025 4:49:28 AM
  • Nuvalent Q2 Loss Per Share $1.39 Vs Loss $0.88 Last Year 8/7/2025 6:55:05 AM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $115 Price Target 7/21/2025 8:55:25 PM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap